Payment overview · 2025
General Payments
$2,095.91
116 reported records · 24 companies
Healthcare provider profile · identity verified
Daniel Jetton Mcgilvray, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORT WORTH, TX · NPI 1386965234
Verified facts
What the public records show
CMS Open Payments records show Daniel Jetton Mcgilvray, DO received $2,095.91 in general payments during 2025 across 116 reported records.
PFIZER INC. accounted for 11.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $247.58 | 11.8% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $233.52 | 11.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $199.29 | 9.5% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $193.08 | 9.2% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.85 | 9.0% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.36 | 8.6% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $175.67 | 8.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $123.18 | 5.9% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $68.94 | 3.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.24 | 3.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.82 | 3.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.76 | 2.6% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $51.59 | 2.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $43.95 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.52 | 1.7% | 2 | 2025 |
| Evofem Biosciences, Inc. | Unresolved — no canonical attribution shown | $23.56 | 1.1% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $22.49 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.51 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.89 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.81 | 0.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.65 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.96 | 0.8% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $14.39 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,095.91 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $263.22 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $179.03 | 15 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $175.67 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $146.71 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.94 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $123.18 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $111.50 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $77.35 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $68.94 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.16 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.02 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $53.76 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.37 | 9 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $43.95 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.54 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.54 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.52 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.33 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $29.07 | 2 | 2025 |
Source payment records
|
|||||
| Phexx Normalized: phexx |
Drug | Evofem Biosciences, Inc. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| Phexxi Normalized: phexxi |
Drug | Evofem Biosciences, Inc. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| Solosec Normalized: solosec |
Drug | Evofem Biosciences, Inc. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 51 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 183 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
183 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 184 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 335 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 80 |
| Lisinopril | Lisinopril | 244 | 78 |
| Metformin Hcl | Metformin Hcl | 211 | 74 |
| Ozempic | Semaglutide | 183 | 40 |
| Omeprazole | Omeprazole | 158 | 53 |
| Gabapentin | Gabapentin | 155 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 53 |
| Losartan Potassium | Losartan Potassium | 123 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 35 |
| Furosemide | Furosemide | 105 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 45 |
| Trazodone Hcl | Trazodone Hcl | 103 | 24 |
| Metformin Hcl Er | Metformin Hcl | 96 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 91 | 26 |
| Montelukast Sodium | Montelukast Sodium | 89 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 27 |
| Sertraline Hcl | Sertraline Hcl | 84 | 25 |
| Potassium Chloride | Potassium Chloride | 79 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 31 |
| Allopurinol | Allopurinol | 75 | 23 |
| Benazepril Hcl | Benazepril Hcl | 70 | 20 |
| Alendronate Sodium | Alendronate Sodium | 66 | 28 |
| Simvastatin | Simvastatin | 66 | 22 |
| Mounjaro | Tirzepatide | 64 | 14 |
| Bupropion Xl | Bupropion Hcl | 62 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 16 |
| Carvedilol | Carvedilol | 61 | 22 |
| Glipizide | Glipizide | 60 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 22 |
| Spironolactone | Spironolactone | 55 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 13 |
| Eliquis | Apixaban | 51 | 16 |
| Jardiance | Empagliflozin | 51 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 19 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 41 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | 11 |
| Finasteride | Finasteride | 34 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | 11 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 14 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 28 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 13 |
| Naproxen | Naproxen | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,095.91 · 116 records | PFIZER INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, INCEPTIV, JARDIANCE, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PAXLOVID, PREVNAR 20, Phexx, Phexxi, QULIPTA, RECORLEV, Rybelsus, SHINGRIX, Secuado, Senza, Solosec, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XHANCE, XIFAXAN, Xelstrym, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error